Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. Foda BM, Misek SA, Gallo KA, Neubig RR, et al. Int J Cancer 2024 Jun 19. doi: 10.1002/ijc.35056.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Foda BM, Misek SA, Gallo KA, Neubig RR, et al. Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. Int J Cancer 2024 Jun 19. doi: 10.1002/ijc.35056.
PMID: 38898604